Medigene AG: Medigene presents posters on immunotherapies at CRI-CIMT-EATI-AACR Conference

Planegg (pta005/16.08.2017/07:30 UTC+2) - First poster reports of a semi-automated method for the isolation and initial characterization of neoantigen-specific T cell receptors (TCRs)
- Second poster describes Medigene's PRAME-specific TCR for adoptive T cell immunotherapy of cancer

Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced that scientists of the Company were invited to present two posters on its T cell receptor (TCR)-modified T cell therapies during the upcoming CRI-CIMT-EATI-AACR Conference. The Cancer Research Institute (CRI), the Association for Cancer lmmunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) sponsor the Third International Cancer lmmunotherapy Conference that takes place in Mainz, Germany, from September 6-9, 2017.

During the "Neoantigens and Cancer Mutations" session, Dr. Christiane Mummert, scientist at Medigene Immunotherapies, will present her poster describing a semi-automated method for the isolation and initial characterization of neoantigen-specific T cell receptors. In summary, the experiments demonstrated that neoantigen-specific TCRs can be isolated from peripheral blood samples of healthy donors and initially characterized in eight to ten weeks using an innovative high-throughput robotics platform.

On the second poster, presented during the "Adoptive Cell Therapy" session, shared co-authors Dr. Christian Ellinger and Dr. Manon Weis describe properties of Medigene's PRAME-specific TCR for adoptive T cell immunotherapy of cancer. Using an innovative TCR isolation and characterization platform, a TCR with natural high avidity for a PRAME-derived epitope was isolated showing potent efficacy and a favorable safety profile that will be further evaluated in clinical trials.

Both posters will be presented during "Poster Session A" that will take place on September 6 between 6:00 pm - 8:00 pm.

About Medigene's TCR technology: The TCR technology aims at arming the patient's own T cells with tumor-specific T cell receptors (TCRs). The receptor-modified T cells are then able to detect and efficiently kill tumor cells. This immunotherapy approach attempts to overcome the patient's tolerance towards cancer cells and tumor-induced immunosuppression by activating and modifying the patient's T cells outside the body (ex vivo).
TCR therapy is developed to utilize a higher number of potential tumor antigens than other T cell-based immunotherapies, such as chimeric antigen receptor T cell (CAR T) therapy. Medigene is preparing the clinical development of its first TCR candidates and is establishing a pipeline of recombinant T cell receptors, and has established Good Manufacturing Practice (GMP)-compliant processes for their combination with patient-derived T cells.

Medigene's first TCR immunotherapy "MDG1011" will be tested in a clinical Phase I/II trial intended to be started by the end of 2017.

Besides the planned company-sponsored TCR trial, Medigene is involved in an investigator-initiated trial (IIT) with TCRs in multiple myeloma (MM) to be conducted by the Charité - Universitätsmedizin Berlin in cooperation with the Max Delbrück Centre (MDC), Berlin.
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with projects currently in preclinical and clinical development.
For more information, please visit http://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg Germany
Contact Person:	Medigene PR/IR
Phone:	+49 89 200033-3301
E-Mail:	public.relations@medigene.com
Website:	www.medigene.de
ISIN(s):	DE000A1X3W00 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate